Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
77 studies found for:    Open Studies | "Scleroderma, Systemic"
Show Display Options
Rank Status Study
1 Recruiting A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Condition: Scleroderma, Systemic
Interventions: Drug: Nintedanib;   Drug: Placebo
2 Recruiting Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Other: blood samples
3 Recruiting Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
4 Not yet recruiting The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Drug: bosentan
5 Recruiting Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Stromal Vascular fraction;   Drug: Ringer lactate
6 Not yet recruiting Oral Manifestations of Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Radiation: Cone Beam Computed Tomography (CBCT)
7 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
8 Recruiting Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Intervention: Drug: Campath
9 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo
10 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
11 Recruiting Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
Condition: Scleroderma
Interventions: Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
12 Recruiting Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Conditions: Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
13 Recruiting Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Other: Magnetic resonance Imaging
14 Recruiting Scleroderma Registry
Conditions: Systemic Sclerosis;   Scleroderma
Intervention:
15 Recruiting A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Abatacept;   Drug: Placebo
16 Recruiting Duke Scleroderma Clinic Patient Registry
Conditions: Scleroderma;   Systemic Sclerosis
Intervention: Other: Registry
17 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
18 Recruiting Conception of an ICF Core Set for Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:
19 Recruiting ADMSCs for the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Biological: injection of autologous stromal vascular fraction
20 Recruiting Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Conditions: Scleroderma, Diffuse;   Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: IVA337;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.